PhaseBio Pharmaceuticals

NasdaqGM:PHAS Stock Report

Mkt Cap: US$39.7m

PhaseBio Pharmaceuticals Past Performance

How has PhaseBio Pharmaceuticals performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PHAS is currently unprofitable.

Growing Profit Margin: PHAS is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: PHAS is unprofitable, and losses have increased over the past 5 years at a rate of 46.4% per year.

Accelerating Growth: Unable to compare PHAS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PHAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: PHAS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Discover strong past performing companies